Abnormalities of the erythrocyte membrane in chronic myelogenous leukemia.

Biotechnol Appl Biochem

Department of Chemistry, Bose Institute, Calcutta, India.

Published: October 1990

Chronic myelogenous leukemia (CML) is a hematologic malignancy characterized by excessive growth of myeloid cells and their progenitors. The proportion of spectrin dimers compared to tetramers extracted from membranes at 4 degrees C, under low ionic strength conditions, increased in CML erythrocytes. These also displayed abnormal thermal sensitivity (between 45 and 46 instead of 49 degrees C). Crosslinking with the bifunctional reagent, dimethyl adipimidate (8.6 A) showed significant organizational modification of not only spectrin, but other cytoskeletal components such as ankyrin, bands 4.2 and 5. Enhanced concanavalin A (Con-A) agglutinability of CML erythrocytes also suggests altered topographic distribution of a functionally important membrane protein, band 3. The anion transport activities of erythrocytes from patients with CML and normal donors were comparable. In CML erythrocytes, significant reduction in the number of ankyrin-binding sites, present in the cytoplasmic domain of band 3, may lead to partial loss of cytoskeletal anchorage to the bilayer and account for their increased Con-A agglutinability and heat sensitivity and may lead to their premature removal from the circulation.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cml erythrocytes
12
chronic myelogenous
8
myelogenous leukemia
8
con-a agglutinability
8
cml
5
abnormalities erythrocyte
4
erythrocyte membrane
4
membrane chronic
4
leukemia chronic
4
leukemia cml
4

Similar Publications

Febuxostat enhances the efficacy of dasatinib by inhibiting ATP-binding cassette subfamily G member 2 (ABCG2) in chronic myeloid leukemia cells.

Biomed Pharmacother

December 2024

Department of Pharmacy, Osaka University Hospital, Suita, Osaka 5650871, Japan; Department of Hospital Pharmacy, Graduate School of Medicine, Osaka University, Suita, Osaka 5650871, Japan.

Article Synopsis
  • - Dasatinib is a medication used to treat chronic myeloid leukemia (CML), but some patients develop resistance due to high levels of the ABCG2 protein in their cancer cells.
  • - A study involving 65 CML patients found that those taking the xanthine oxidase inhibitor febuxostat alongside dasatinib had better treatment outcomes, with significantly higher rates of early and major molecular response.
  • - Laboratory experiments showed that febuxostat can lower cell viability and increase dasatinib levels in CML cells, suggesting it helps enhance dasatinib's effects by reducing ABCG2's ability to eject the drug from cells, which may offer new ways to tackle TKI resistance in CML treatment. *
View Article and Find Full Text PDF
Article Synopsis
  • * Research is exploring the use of traditional Chinese medicine, specifically total saponin of L. (TSRP), which has shown promise in inhibiting CML cell growth and potentially reversing imatinib resistance.
  • * This project aims to understand how TSRP impacts the PI3K/AKT signaling pathway, which is linked to imatinib resistance, through in vitro and in vivo experiments, to support TSRP's use alongside imatinib in CML treatment.
View Article and Find Full Text PDF

Background: Chronic Myeloid Leukemia (CML), accounting for 15-20% of adult leukemia cases, is marked by the Philadelphia chromosome, resulting from the t(9;22)(q34;q11) translocation. This leads to uncontrolled cell proliferation and survival. Imatinib therapy lowers BCR-ABL levels, influencing telomere-associated proteins and increasing telomerase accessibility, indirectly boosting its activity.

View Article and Find Full Text PDF

Progesterone (P4) has an important effect (activatory or inhibitory) on cell proliferation. Although there is evidence of the impact of progesterone on sex-linked cancers, it can affect other cancer cells expressing P4 receptors (PRs). We evaluated the expression of membrane P4 receptors (mPRs) and the viability in progesterone-treated K562 cells to inspect the possible effects route of progesterone on this (CML) cancer cell line.

View Article and Find Full Text PDF

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by excessive proliferation of myeloid cells. The COVID-19 pandemic has raised concerns regarding the impact of SARS-CoV-2 on patients with malignancies, particularly those with CML. This study aimed to investigate the effects of SARS-CoV-2 proteins on CML cell viability and the protective role of vitamin K2 (VK2) in conjunction with imatinib.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!